Other
18 Authors
- Mitchell DA,
- Wang Y,
- Deng W,
- Yang M,
- Yang Z,
- Qie Y,
- Johnson AJ,
- Zhao H,
- Jiang W,
- Chan CK,
- Kim BYS,
- Rosenfeld SS,
- Yun K,
- Lee AS,
- von Roemeling CA,
- Yuan H,
- Bruno KA,
- Liu X
| First Author | von Roemeling CA | Year | 2020 |
| Journal | Nat Commun | Volume | 11 |
| Issue | 1 | Pages | 1508 |
| PubMed ID | 32198351 | Mgi Jnum | J:286385 |
| Mgi Id | MGI:6401571 | Doi | 10.1038/s41467-020-15129-8 |
| Citation | von Roemeling CA, et al. (2020) Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun 11(1):1508 |
| abstractText | Tumour cell phagocytosis by antigen presenting cells (APCs) is critical to the generation of antitumour immunity. However, cancer cells can evade phagocytosis by upregulating anti-phagocytosis molecule CD47. Here, we show that CD47 blockade alone is inefficient in stimulating glioma cell phagocytosis. However, combining CD47 blockade with temozolomide results in a significant pro-phagocytosis effect due to the latter's ability to induce endoplasmic reticulum stress response. Increased tumour cell phagocytosis subsequently enhances antigen cross-presentation and activation of cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) in APCs, resulting in more efficient T cell priming. This bridging of innate and adaptive responses inhibits glioma growth, but also activates immune checkpoint. Sequential administration of an anti-PD1 antibody overcomes this potential adaptive resistance. Together, these findings reveal a dynamic relationship between innate and adaptive immune regulation in tumours and support further investigation of phagocytosis modulation as a strategy to enhance cancer immunotherapy responses. |
